--- title: "MREO 截止日期：Rosen 律師事務所敦促 Mereo BioPharma Group plc（納斯達克代碼：MREO）持有損失超過 10 萬美元的股東聯繫該事務所，以瞭解他們的權利信息" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/281649896.md" description: "羅森律師事務所呼籲在 Mereo BioPharma Group plc（納斯達克代碼：MREO）投資的股東，如果其損失超過 10 萬美元，請與他們聯繫，參與集體訴訟。該訴訟涉及對 Mereo 在其商業運營方面的誤導性陳述，特別是關於第三階段 ORBIT 和 COSMIC 項目的指控。希望擔任主要原告的股東必須在 2026 年 4 月 6 日之前提交動議。羅森律師事務所採用風險代理收費模式，意味着在未實現賠償之前不收取任何費用" datetime: "2026-04-03T15:42:25.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281649896.md) - [en](https://longbridge.com/en/news/281649896.md) - [zh-HK](https://longbridge.com/zh-HK/news/281649896.md) --- # MREO 截止日期：Rosen 律師事務所敦促 Mereo BioPharma Group plc（納斯達克代碼：MREO）持有損失超過 10 萬美元的股東聯繫該事務所，以瞭解他們的權利信息 **MREO Deadline: Rosen Law Firm Urges** **Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights** Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of American Depositary Shares (“ADS”) of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023, and December 26, 2025. Mereo describes itself as a “biopharmaceutical company focused on the development of therapeutics for rare diseases.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Mereo BioPharma Group plc (NASDAQ: MREO) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants made false and/or misleading statements and/or concealed material adverse facts concerning the true state of the Phase 3 ORBIT and COSMIC programs; neither of which hit its primary endpoints of reducing annualized clinical fracture rate compared to the placebo or bisphosphonate control groups, respectively. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Mereo BioPharma Group plc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by April 6, 2026. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen\_firm or on Facebook: https://www.facebook.com/rosenlawfirm/. Attorney Advertising. Prior results do not guarantee a similar outcome. Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260403663845/en/ ### 相關股票 - [MREO.US](https://longbridge.com/zh-HK/quote/MREO.US.md) ## 相關資訊與研究 - [國富氫能 360 萬美元認購納斯達克上市公司 UCAR 股份](https://longbridge.com/zh-HK/news/284293362.md) - [永豐金證券豐股務把關 股東會紀念品「豐」收不遺漏](https://longbridge.com/zh-HK/news/284329539.md) - [2026 年股東週年大會投票表決結果及新委任香港交易所董事會成員](https://longbridge.com/zh-HK/news/284557180.md) - [美股創新高卻消費者信心下滑，市場信號矛盾與 AI 競爭激烈引發擔憂](https://longbridge.com/zh-HK/news/284059273.md) - [六九一二：諾德基金分多個產品持股未進前十大股東](https://longbridge.com/zh-HK/news/284338390.md)